Ralinepag Reduced Pulmonary Arterial Hypertension Progression
Phase 3 trial results show ralinepag significantly reduced the risk of worsening symptoms and improved exercise capacity in pulmonary arterial hypertension patients.
Tag: CTEPH PAH and pulmonary hypertension
All
Latest
Ralinepag Reduced Pulmonary Arterial Hypertension Progression
Phase 3 trial results show ralinepag significantly reduced the risk of worsening symptoms and improved exercise capacity in pulmonary arterial hypertension patients.
Read More
New Data on Inhaled Treprostinil for IPF
Data from clinical trials investigating treatments for pulmonary hypertension and pulmonary fibrosis will be highlighted at ATS 2026.
Read More
Airgas Therapeutics Ulspira iNO Therapy
The Ulspira Solution combines inhaled nitric oxide (iNO) gas with a portable delivery system and clinical support to treat infants with hypoxic respiratory failure.
Read More
Insmed Presents Data on TPIP Inhalation Drug for PAH
Insmed will present four abstracts on treprostinil palmitil inhalation powder (TPIP), being evaluated as a once-daily therapy for the treatment of patients with PAH, PH-ILD, and other rare and serious pulmonary disorders.
Read More
FDA Expands Winrevair Approval for Pulmonary Arterial Hypertension
Winrevair is now FDA-approved to treat pulmonary arterial hypertension to improve exercise capacity and reduce the risk of clinical worsening events, including hospitalization for PAH, lung transplantation and death.
Read More
GLP-1 RAs Versus SGLT2 Inhibitors for Heart Failure Risk in PAH
GLP-1 RAs may provide added benefit over SGLT2-i in protecting right heart function among patients with PAH.
Read More
Inhaled Treprostinil Improves Cardiac Effort in PH-ILD Patients
Treatment with an inhaled dry powder formulation of treprostinil was associated with improvements in cardiac effort for patients with pulmonary hypertension–interstitial lung disease (PH-ILD).
Read More
Winrevair Reduced Risks of PAH Worsening Events
Results from a Phase 3 clinical study of adults with pulmonary arterial hypertension found Winrevair reduced the risk of clinical worsening events by 76%.
Read More
Innovations in Inhaled Nitric Oxide Delivery
In this edition of our “Industry Analysis” series, RT magazine speaks with manufacturers of inhaled nitric oxide delivery systems about the latest market innovations in the iNO industry.
Read More
Pulmonary Artery Denervation Had Clinical Benefits in Pulmonary Hypertension
Pulmonary artery denervation (PADN) could reduce mean right atrial pressure, mean pulmonary artery pressure, and pulmonary vascular resistance in pulmonary hypertension patients.
Read More
FDA Grants Orphan Drug Status to Pulmonary Arterial Hypertension Treatment
ZMA001, in development for pulmonary arterial hypertension, has been designated as an Orphan Drug by the US Food and Drug Administration.
Read More
Hormone Replacement Therapy May Improve Pulmonary Hypertension
Use of hormone replacement therapy (HRT) in women was associated with lower mean pulmonary artery pressure and higher right ventricular fractional shortening and right ventricular ejection fraction, according to research presented at ATS 2024.
Read More
FDA Approves Merck’s Injection for Pulmonary Arterial Hypertension
The injection on top of background therapy significantly improved exercise capacity and multiple secondary outcome measures compared to background therapy alone.
Read More
Aria CV Implants First Patient with Pulmonary Hypertension System
Aria CV Inc reports its first patient was implanted with the Gen 2 Aria CV Pulmonary Hypertension System.
Read More
Cell-based Therapy Safe for Pulmonary Arterial Hypertension
Infusions of potentially therapeutic cells derived from the heart are safe for people with pulmonary arterial hypertension, according to a study led by Cedars-Sinai investigators.
Read More
Guidance for Diagnosis and Treatment of Pulmonary Hypertension Related to ILD
The Pulmonary Fibrosis Foundation and Pulmonary Hypertension Association have developed a position statement that addresses gaps in the diagnosis and treatment of patients living with pulmonary hypertension related to interstitial lung disease.
Read More
Cleveland Clinic Pulmonologist Takes Helm at Pulmonary Fibrosis Foundation
The Pulmonary Fibrosis Foundation announced Franck Rahaghi, MD, MHS, FCCP, as its incoming president, CEO, and chief medical officer, effective Sept 15.
Read More
Pulmonary Rehabilitation Gets ‘Strong’ Recommendation in New ATS Guideline
The latest guideline from the American Thoracic Society reaffirms benefits for patients with COPD as well as pulmonary hypertension and interstitial lung disease.
Read More
NOxBOXi Nitric Oxide Systems Recalled
The recall was issued due to a misalignment of the check valve in the device’s manifold, which may cause the manifold to fail and interrupt therapy to neonates.
Read More
Janssen Submits New Drug Application for Investigational Single-Tablet Combo Therapy to Treat PAH
The Janssen Pharmaceutical Companies of Johnson & Johnson is seeking FDA approval of an investigational single-tablet combination therapy of macitentan and tadalafil for the long-term treatment of pulmonary arterial hypertension.
Read More
Lung Care Provider Guide Available to Enhance Quality of Life for Lung Disease Patients
The new guide can assist providers in learning and practicing skills to prevent or manage respiratory symptoms in patients with chronic lung disease.
Read More
Complications for Balloon Technique for CTEPH Patients Decrease Significantly
A Michigan Medicine-led study reveals that the once-feared severe complications that occur during balloon pulmonary angioplasty have dropped in recent years.
Read More
Market Analysis: The Impact of Cylinder-free Systems on Inhaled Nitric Oxide Delivery
RT magazine spoke with manufacturers of inhaled nitric oxide delivery systems about the latest market innovations in the iNO industry, specifically about the impact of cylinder-free (“tankless”) systems, plus research on its potential use to treat other cardiopulmonary diseases.
Read More
Combo Pill for Pulmonary Hypertension Outperforms Monotherapy
The outcomes for patients with pulmonary arterial hypertension taking macitentan and tadalafil together in a single pill have been detailed in a new study, which shows significant improvement compared to those taking either drug alone.
Read More